Abstract:
BACKGROUND:Exercise has favorable effects on biomarkers associated with a lower risk of breast cancer, however it is unclear if higher doses of exercise provide additional effects. No clinical trial has systematically examined how different exercise volumes influence the mechanisms underlying breast cancer etiology. The Breast Cancer and Exercise Trial in Alberta (BETA) - a follow-up study to the Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial - is examining how a one-year, high versus moderate volume aerobic exercise intervention influences several biomechanisms hypothesized to influence breast cancer risk in a group of postmenopausal women. Secondary aims are to compare intervention effects on psychosocial and quality of life outcomes as well as understand exercise adherence at 12 and 24 months, and maintenance of all study outcomes at 24 months. METHODS/DESIGN:The BETA Trial is a two-center, two-armed randomized controlled exercise intervention trial conducted in 400 previously inactive, postmenopausal women aged 50-74 years, in Alberta, Canada. Participants were randomly assigned to a one-year aerobic exercise intervention of either high volume (300 minutes/week) or moderate volume (150 minutes/week). Blood draws and accelerometry were performed at baseline, six and 12 months. Baseline and 12-month measurements were taken of adiposity (including dual energy X-ray absorptiometry and computed tomography scans), physical fitness, dietary intake, self-reported physical activity and sedentary behavior, quality of life, perceived stress, happiness, sleep, and determinants of exercise adherence. Exercise maintenance was assessed and all study measurements were repeated at 24 months. Blood will be analyzed for endogenous estrogens, insulin resistance indicators, and inflammatory markers. DISCUSSION:The BETA Trial will compare the impact of a high versus moderate volume of aerobic exercise on a variety of biological, physiological, and psychological outcomes of relevance to postmenopausal women. A tightly controlled exercise intervention and objective outcome measurements are methodological strengths. The BETA Trial will inform future prevention initiatives by assessing adherence to a high volume of exercise over 12 months by postmenopausal women, and the ability of these women to maintain activity over the longer-term. The ultimate objective is to inform public health guidelines for reducing breast cancer risk through physical activity. TRIAL REGISTRATION: CLINICAL TRIALS REGISTRATION NUMBER:NCT01435005.
journal_name
BMC Cancerjournal_title
BMC cancerauthors
Friedenreich CM,MacLaughlin S,Neilson HK,Stanczyk FZ,Yasui Y,Duha A,Lynch BM,Kallal C,Courneya KSdoi
10.1186/1471-2407-14-919subject
Has Abstractpub_date
2014-12-06 00:00:00pages
919issn
1471-2407pii
1471-2407-14-919journal_volume
14pub_type
杂志文章,多中心研究,随机对照试验相关文献
BMC CANCER文献大全abstract:BACKGROUND:Conditional survival (CS) measures the probability that patients will survive an additional number of years given that they have already survived for a certain period of time. METHODS:In total, 2935 gastric cancer patients who had undergone curative gastrectomy between 1995 and 2011 were enrolled. The Cox p...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-2022-2
更新日期:2015-12-23 00:00:00
abstract:BACKGROUND:Wnt-2 plays an oncogenic role in cancer, but which Frizzled receptor(s) mediates the Wnt-2 signaling pathway in lung cancer remains unclear. We sought to (1) identify and evaluate the activation of Wnt-2 signaling through Frizzled-8 in non-small cell lung cancer, and (2) test whether a novel expression const...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-316
更新日期:2013-07-01 00:00:00
abstract:BACKGROUND:PRDM5 is an epigenetic regulator that has been recognized as an important tumour suppressor gene. Silencing of PRDM5 by promoter hypermethylation has been demonstrated in several cancer types and PRDM5 loss results in upregulation of the Wnt pathway and increased cellular proliferation. PRDM5 has not been ex...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1011-9
更新日期:2015-01-23 00:00:00
abstract:BACKGROUND:Based on their different mechanisms of action, non-overlapping side effects and radiosensitising potential, combining the antimetabolites pemetrexed (multitargeted antifolate, MTA) and gemcitabine (2',2'-difluorodeoxycytidine, dFdC) with irradiation (RT) seems promising. This in vitro study, for the first ti...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-10-441
更新日期:2010-08-19 00:00:00
abstract:BACKGROUND:Currently there are very few biomarkers to identify head and neck squamous cell carcinoma (HNSCC) cancer patients at a greater risk of recurrence and shortened survival. This study aimed to investigate whether a marker of systemic inflammation, the neutrophil-to-lymphocyte ratio (NLR), was predictive of clin...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2089-4
更新日期:2016-02-18 00:00:00
abstract:BACKGROUND:We evaluated the hierarchical risk groups for the estimated survival of WHO grade III glioma patients using recursive partitioning analysis (RPA). To our knowledge, this is the first study to address the results of RPA specifically for WHO grade III gliomas. METHODS:A total of 133 patients with anaplastic a...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-450
更新日期:2009-12-18 00:00:00
abstract:BACKGROUND:Transforming growth factor (TGF)-β plays a pivotal role in cancer progression through regulating cancer cell proliferation, invasion, and remodeling of the tumor microenvironment. Cancer-associated fibroblasts (CAFs) are the predominant type of stromal cell, in which TGF-β signaling is activated. Among the s...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-580
更新日期:2014-08-09 00:00:00
abstract:BACKGROUND:There is an unmet clinical need for better prognostic and diagnostic tools for renal cell carcinoma (RCC). METHODS:Human Protein Atlas data resources, including the transcriptomes and proteomes of normal and malignant human tissues, were searched for RCC-specific proteins and cubilin (CUBN) identified as a ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-3030-6
更新日期:2017-01-04 00:00:00
abstract:BACKGROUND:Cancers of unknown primary origin (CUPs) are reported to be the 3-4th most common causes of cancer death. Recent years have seen advances in mutational analysis and genomics profiling. These advances could improve accuracy of diagnosis of CUPs and might improve the prognosis of patients with CUPs. CASE PRES...
journal_title:BMC cancer
pub_type: 杂志文章,评审
doi:10.1186/s12885-019-5277-1
更新日期:2019-01-11 00:00:00
abstract:BACKGROUND:Territorial differences in the access to innovative anticancer drugs have been reported from many countries. The objectives of this study were to evaluate access to innovative treatments for metastatic lung cancer in France, and to assess whether socioeconomic indicators were predictors of access at the leve...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4958-5
更新日期:2018-10-22 00:00:00
abstract:BACKGROUND:MicroRNA-21 (miR-21) has been suggested to play a significant role in the prognosis of carcinoma. The recognition of novel biomarkers for the prediction of cancer outcomes is urgently required. However, the potential prognostic value of miR-21 in various types of human malignancy remains controversial. The p...
journal_title:BMC cancer
pub_type: 杂志文章,meta分析,评审
doi:10.1186/1471-2407-14-819
更新日期:2014-11-07 00:00:00
abstract:BACKGROUND:Glioblastoma relapses in the vast majority of cases within 1 year. Maximum safe resection of the recurrent glioblastoma can be offered in some cases. Re-irradiation has been established for the treatment of recurrent glioblastoma, too. In both cases, adjuvant treatment, mostly using temozolomide, can improve...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/s12885-017-3928-7
更新日期:2018-01-03 00:00:00
abstract:BACKGROUND:Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice. METHO...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1512-6
更新日期:2015-07-04 00:00:00
abstract:BACKGROUD:The incidence of recurrent laryngeal nerve (RLN) injury has increased due to RLN lymph node dissection. The aim of this study was to evaluate the ability of intraoperative ultrasonography (IU) to detect RLN nodal metastases in esophageal cancer patients. METHODS:Sixty patients with esophageal cancer underwen...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4643-8
更新日期:2018-07-13 00:00:00
abstract:BACKGROUND:The incidence of thyroid cancer and the number of patients who die from this disease are increasing globally. Differentiated thyroid cancer (DTC) is the histologic subtype present in most patients and is primarily responsible for the increased overall incidence of thyroid cancer. Sorafenib is a multikinase i...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/1471-2407-11-349
更新日期:2011-08-11 00:00:00
abstract:BACKGROUND:SET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in transcriptional elongation. There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it could be implicated in the process of carcinogenesis. Furthermore, this gene is ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-290
更新日期:2009-08-21 00:00:00
abstract:BACKGROUND:We analyzed the influence of 8 germinal polymorphisms of candidate genes potentially related to EGFR signalling (EGFR, EGF, CCND1) or antibody-directed cell cytotoxicity (FCGR2A and FCGR3A) on outcome of colorectal cancer (CRC) patients receiving cetuximab-based therapy. METHODS:Fifty-eight advanced CRC pat...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-496
更新日期:2011-11-25 00:00:00
abstract:BACKGROUND:Deaf people represent 0.1% of the French population and their access to public health campaigns is limited due to their frequent illiteracy and the infrequent use of sign language in campaigns. There is also a lack of general health knowledge in spite of the existence of French Deaf Care Units (UASS). The ai...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3972-3
更新日期:2018-01-23 00:00:00
abstract:BACKGROUND:Deciphering the meaning of the human DNA is an outstanding goal which would revolutionize medicine and our way for treating diseases. In recent years, non-coding RNAs have attracted much attention and shown to be functional in part. Yet the importance of these RNAs especially for higher biological functions ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-6338-1
更新日期:2019-12-03 00:00:00
abstract:BACKGROUND:MicroRNAs are the endogenous small non-coding RNA molecules capable of silencing protein coding genes at the posttranscriptional level. Based on computer-aided predictions, a single microRNA could have over a hundred of targets. On the other hand, a single protein-coding gene could be targeted by many potent...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-194
更新日期:2009-06-18 00:00:00
abstract:BACKGROUND:Perturbing Hsp90 chaperone function targets hypoxia inducible factor (HIF) function in a von Hippel-Lindau (VHL) independent manner, and represents an approach to combat the contribution of HIF to cell renal carcinoma (CCRCC) progression. However, clinical trials with the prototypic Hsp90 inhibitor 17-AAG ha...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-520
更新日期:2011-12-15 00:00:00
abstract:BACKGROUND:Cervical cancer is the 4th highest cause of female reproductive tract malignancies. Multiple loci have been identified as important determinant factors for tumor susceptibility. In this report, we aimed to explore the roles of gene polymorphisms affecting x-ray repair cross complementing 1 (XRCC1), the tumor...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-5149-0
更新日期:2019-01-07 00:00:00
abstract:BACKGROUND:To assess the safety and efficacy of simultaneous integrated boost (SIB) or late course accelerated boost (LCAB) with external beam radiotherapy (EBRT) to the vaginal cuff for high risk cervical cancer patients after radical hysterectomy. METHODS:Between October 2009 and January 2012, patients with high ris...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1248-3
更新日期:2015-04-11 00:00:00
abstract:BACKGROUND:Acute myeloid leukemia (AML) is a heterogenic lethal disorder characterized by the accumulation of abnormal myeloid progenitor cells in the bone marrow which results in hematopoietic failure. Despite various efforts in detection and treatment, many patients with AML die of this cancer. That is why it is impo...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-06903-4
更新日期:2020-05-18 00:00:00
abstract:BACKGROUND:Treatment of locally advanced non-small-cell lung cancer is based on a combined approach. To study the impact of trimodal therapy for stage III-N2 NSCLC a single centre retrospective evaluation focusing on survival and therapy-related toxicity was performed. METHODS:71 patients diagnosed between March 2001 ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-572
更新日期:2014-08-07 00:00:00
abstract:BACKGROUND:Lymphangiogenesis has become a new research frontier in tumor metastasis since the discovery of reliable lymphatic markers that have allowed observation and isolation of lymphatic endothelium. Cyclooxygenase-2 (COX-2) has been reported to be involved in the critical steps in carcinogenesis. However, possible...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-8-4
更新日期:2008-01-13 00:00:00
abstract:BACKGROUND:In China, there are currently no approved therapies for the treatment of metastatic renal cell carcinoma (mRCC) following progression with vascular endothelial growth factor (VEGF)-targeted agents. In the phase 3 RECORD-1 trial, the mammalian target of rapamycin (mTOR) inhibitor everolimus afforded clinical ...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/1471-2407-13-136
更新日期:2013-03-21 00:00:00
abstract:BACKGROUND:Among American men, prostate cancer is the most common, non-cutaneous malignancy that accounted for an estimated 241,000 new cases and 34,000 deaths in 2011. Previous studies have suggested that Wnt pathway inhibitory genes are silenced by CpG hypermethylation, and other studies have suggested that genistein...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-12-145
更新日期:2012-04-11 00:00:00
abstract:BACKGROUND:Several studies have reported the role of CYP2A6 genetic polymorphisms in smoking and lung cancer risk with some contradictory results in different populations. The purpose of the current study is to assess the contribution of the CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 gene polymorphisms and tobacco smok...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4342-5
更新日期:2018-05-03 00:00:00
abstract:BACKGROUND:The aim of this study was to assess the feasibility and potential benefit of a brief psychosocial intervention based on cognitive-behavioral therapy performed in addition to early palliative care (PC) in the reduction of depressive symptoms among patients with advanced cancer. METHODS:An open-label randomiz...
journal_title:BMC cancer
pub_type: 杂志文章,随机对照试验
doi:10.1186/s12885-017-3560-6
更新日期:2017-08-23 00:00:00